Relapse occurrence in only some ADAMTS13-deficient TTP patients [1] suggests the potential for biologic heterogeneity in the TTP patient population that could contribute to relapse risk. This evidence concerns the gene ADAMTS13 and thrombotic thrombocytopenic purpura.